Literature DB >> 19207960

How to use virological tools for optimal management of chronic hepatitis C.

Stéphane Chevaliez1, Jean-Michel Pawlotsky.   

Abstract

Chronic hepatitis C is a global health problem that may cause cirrhosis and progression to hepatocellular carcinoma. Currently available antiviral treatments are moderately effective. Several virological assays are available to help diagnose and manage patients infected with the hepatitis C virus (HCV). These include the anti-HCV antibody assays, measurement of HCV RNA viral load and HCV genotyping. HCV RNA can be assayed by two types of molecular biology-based techniques: target amplification as in polymerase chain reaction methods and signal amplification such as the branched DNA assay. Monitoring of viral kinetics during the early phases of antiviral treatment is crucial in making treatment decisions such as early stopping rules and also in optimizing the length of treatment. The HCV genotype can be determined by several methods. Whatever the method, pretreatment determination allows treatment length and ribavirin dose to be optimized and also offers prognostic information on treatment outcomes as certain genotypes respond more favourably to treatment. Thus, virological assays are indispensable in the diagnosis and management of individuals infected with the HCV.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19207960     DOI: 10.1111/j.1478-3231.2008.01926.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity.

Authors:  Johannes Vermehren; Giuseppe Colucci; Peter Gohl; Nabila Hamdi; Ahmed Ihab Abdelaziz; Ursula Karey; Diana Thamke; Heike Zitzer; Stefan Zeuzem; Christoph Sarrazin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

2.  Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics.

Authors:  Ingmar Mederacke; Birgit Bremer; Benjamin Heidrich; Janina Kirschner; Katja Deterding; Thomas Bock; Karsten Wursthorn; Michael P Manns; Heiner Wedemeyer
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Genotyping of hepatitis C virus by sequence analysis of the amplicon from the Roche Cobas AmpliPrep/Cobas TaqMan viral load assay.

Authors:  Todd S Laughlin; Bonnie Nuccie; Paul G Rothberg
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

Review 4.  Hepatitis C virus: Virology, diagnosis and treatment.

Authors:  Hui-Chun Li; Shih-Yen Lo
Journal:  World J Hepatol       Date:  2015-06-08

5.  Quantification of hepatitis C virus (HCV) RNA in a multicenter study: implications for management of HCV genotype 1-infected patients.

Authors:  Giulio Pisani; Karen Cristiano; Francesco Marino; Francesca Luciani; Guillermo M Bisso; Claudio Mele; Daniela Adriani; Giuliano Gentili; Maria Wirz
Journal:  J Clin Microbiol       Date:  2009-07-15       Impact factor: 5.948

6.  Hepatoprotective effect of commercial herbal extracts on carbon tetrachloride-induced liver damage in Wistar rats.

Authors:  Paula Cordero-Pérez; Liliana Torres-González; Marcelino Aguirre-Garza; Carlos Camara-Lemarroy; Francisco Guzmán-de la Garza; Gabriela Alarcón-Galván; Homero Zapata-Chavira; Ma de Jesús Sotelo-Gallegos; Cipactli Nadjedja Torres-Esquivel; Ethel Sánchez-Fresno; Daniel Cantú-Sepúlveda; Gerardo González-Saldivar; Judith Bernal-Ramirez; Linda E Muñoz-Espinosa
Journal:  Pharmacognosy Res       Date:  2013-07

7.  A reliable multiplex genotyping assay for HCV using a suspension bead array.

Authors:  Yi-Chen Yang; Der-Yuan Wang; Hwei-Fang Cheng; Eric Y Chuang; Mong-Hsun Tsai
Journal:  Microb Biotechnol       Date:  2014-07-10       Impact factor: 5.813

8.  Anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia.

Authors:  Hyon-Suk Kim
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.